Compare Automatic Data Processing Inc (ADP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Novo Nordisk A/S — how do they compare? Automatic Data Processing Inc trades at $267.69 (market cap $107.69B), while Novo Nordisk A/S trades at $46.2 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| ADP | NVO | |
|---|---|---|
Market Cap | $107.69B | $207.85B |
Sector | Industrials | Health |
52-Week High | $309.03 | $63.98 |
52-Week Low | $188.79 | $35.29 |
Enterprise Value | $108.73B | $222.55B |
Dividend Yield | 2.51% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $268.23, down 1.99% over the past day, with a bullish technical signal from moving averages and a consensus analyst price target of $280.50. The company reported strong earnings beats in recent quarters, with Q4 2026 EPS of $2.62 beating expectations, and maintains robust profitability with a net income margin of 20.11%. Recent news highlights dividend declarations and positive earnings momentum, though valuation ratios like a P/E of 24.78 suggest a premium.
The outlook for ADP is supported by consistent earnings growth and solid cash flow, but high valuation multiples and competitive pressures in payroll processing pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.78, while macroeconomic labor market trends could impact performance. Analyst sentiment is mixed, with 63.89% holding, indicating cautious optimism amid elevated pricing.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
